A Phase II Study of Docetaxel and Oxaliplatin for Second-Line Treatment of Urothelial Carcinoma

od Srinivas, Sandy, Harshman, Lauren C.
Wydane 2009

The bevacizumab experience in advanced renal cell carcinoma

od Harshman, Lauren C, Srinivas, Sandy
Wydane 2010

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer

od Harshman, Lauren C., Taplin, Mary-Ellen
Wydane 2013

Harnessing the PD-1 Pathway in Renal Cell Carcinoma: Current Evidence and Future Directions

od Tripathi, Abhishek, Drake, Charles G., Harshman, Lauren C.
Wydane w BioDrugs (2014)

Impact of Common Medications on Serum Total Prostate-Specific Antigen Levels: Analysis of the National Health and Nutrition Examination Survey

od Chang, Steven L., Harshman, Lauren C., Presti, Joseph C.
Wydane 2010

PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond

od Harshman, Lauren C., Drake, Charles G., Choueiri, Toni K.
Wydane w Cancer Immunol Res (2014)

Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma

od Minamimoto, Ryogo, Barkhodari, Amir, Harshman, Lauren, Srinivas, Sandy, Quon, Andrew
Wydane w PLoS One (2016)

Subverting the B7-H1/PD-1 Pathway in Advanced Melanoma and Kidney Cancer

od Harshman, Lauren C., Choueiri, Toni K., Drake, Charles, Hodi, F. Stephen
Wydane w Cancer J (2014)

Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients

od Harshman, Lauren C., Bepler, Gerold, Zheng, Zhong, Higgins, John P., Allen, Genevera I., Srinivas, Sandy
Wydane 2010

Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer

od Narayanan, Sujata, Lam, Anthony, Vaishampayan, Ulka, Harshman, Lauren, Fan, Alice, Pachynski, Russell, Poushnejad, Shermeen, Haas, Denise, Li, Shufeng, Srinivas, Sandy
Wydane w Clin Genitourin Cancer (2016)

Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer

od Wang, Xiaodong, Harshman, Lauren C., Xie, Wanling, Nakabayashi, Mari, Qu, Fangfang, Pomerantz, Mark M., Lee, Gwo-Shu Mary, Kantoff, Philip W.
Wydane w J Clin Oncol (2016)

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series

od Martini, Dylan J., Lalani, Aly-Khan A., Bossé, Dominick, Steinharter, John A., Harshman, Lauren C., Hodi, F. Stephen, Ott, Patrick A., Choueiri, Toni K.
Wydane w J Immunother Cancer (2017)

Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805)

od Harshman, Lauren C., Wang, X. Victoria, Hamid, Anis A., Santone, Gabriella, Drake, Charles G., Carducci, Michael A., DiPaola, Robert S., Fichorova, Raina N., Sweeney, Christopher J.
Wydane w Prostate (2020)

Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States

od Allard, Christopher B., Gelpi-Hammerschmidt, Francisco, Harshman, Lauren C., Choueiri, Toni K., Faiena, Izak, Modi, Parth, Chung, Benjamin I., Tinay, Ilker, Singer, Eric A., Chang, Steven L.
Wydane w Urol Oncol (2015)

Time of Metastatic Disease Presentation and Volume of Disease are Prognostic for Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

od Francini, Edoardo, Gray, Kathryn P., Xie, Wanling, Shaw, Grace K., Valença, Loana, Bernard, Brandon, Albiges, Laurence, Harshman, Lauren C., Kantoff, Philip W., Taplin, Mary-Ellen, Sweeney, Cristopher J.
Wydane w Prostate (2018)

Radium-223 dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases

od McKay, Rana R., Bossé, Dominick, Gray, Kathryn P., Michaelson, M. Dror, Krajewski, Katherine, Jacene, Heather A., Walsh, Meghara, Bellmunt, Joaquim, Pomerantz, Mark, Harshman, Lauren C., Choueiri, Toni K.
Wydane w Clin Cancer Res (2018)

Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-d...

od Kamran, Sophia C., Harshman, Lauren C., Bhagwat, Mandar S., Muralidhar, Vinayak, Nguyen, Paul L., Martin, Neil E., La Follette, Stephanie, Faso, Sarah, Viswanathan, Akila N., Efstathiou, Jason A., Beard, Clair J.
Wydane w Adv Radiat Oncol (2017)

The Khorana score in predicting venous thromboembolism for metastatic urothelial carcinoma and variant histology patients treated with chemotherapy

od Ramos, Jorge D., Casey, Martin F., Bamias, Aristotelis, De Giorgi, Ugo, Bellmunt, Joaquim, Harshman, Lauren C., Ladoire, Sylvain, Wong, Yu-Ning, Alva, Ajjai S., Rosenberg, Jonathan E., Galsky, Matthew D., Yu, Evan Y.
Wydane w Clin Appl Thromb Hemost (2016)

A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer

od Choudhury, Atish D., Gray, Kathryn P., Supko, Jeffrey G., Harshman, Lauren C., Taplin, Mary-Ellen, Pace, Amanda Fredericks, Farina, Matthew, Zukotynski, Katherine A., Bernard, Brandon, Kantoff, Philip W., Pomerantz, Mark, Sweeney, Christopher
Wydane w Prostate (2018)

Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer

od Harshman, Lauren C., Wang, Xiaodong, Nakabayashi, Mari, Xie, Wanling, Valenca, Loana, Werner, Lillian, Yu, Yongjiang, Kantoff, Aaron M., Sweeney, Christopher J., Mucci, Lorelei A., Pomerantz, Mark, Lee, Gwo-Shu Mary, Kantoff, Philip W.
Wydane w JAMA Oncol (2015)